{"doi":"10.1093/cid/ciac511","title":"Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study","abstract":"BACKGROUND: Rifampin-resistant and/or multidrug-resistant tuberculosis (RR/MDR-TB) treatment requires multiple drugs, and outcomes remain suboptimal. Some drugs are associated with improved outcome. It is unknown whether particular pharmacokinetic-pharmacodynamic relationships predict outcome. METHODS: Adults with pulmonary RR/MDR-TB in Tanzania, Bangladesh, and the Russian Federation receiving local regimens were enrolled from June 2016 to July 2018. Serum was collected after 2, 4, and 8 weeks for each drug's area under the concentration-time curve over 24 hours (AUC0-24). Quantitative susceptibility of the M. tuberculosis isolate was measured by minimum inhibitory concentrations (MICs). Individual drug AUC0-24/MIC targets were assessed by adjusted odds ratios (ORs) for favorable treatment outcome, and hazard ratios (HRs) for time to sputum culture conversion. K-means clustering algorithm separated the cohort of the most common multidrug regimen into 4 clusters by AUC0-24/MIC exposures. RESULTS: Among 290 patients, 62 (21%) experienced treatment failure, including 30 deaths. Moxifloxacin AUC0-24/MIC target of 58 was associated with favorable treatment outcome (OR, 3.75; 95% confidence interval, 1.21-11.56; P = .022); levofloxacin AUC0-24/MIC of 118.3, clofazimine AUC0-24/MIC of 50.5, and pyrazinamide AUC0-24 of 379 mg × h/L were associated with faster culture conversion (HR >1.0, P < .05). Other individual drug exposures were not predictive. Clustering by AUC0-24/MIC revealed that those with the lowest multidrug exposures had the slowest culture conversion. CONCLUSIONS: Amidst multidrug regimens for RR/MDR-TB, serum pharmacokinetics and M. tuberculosis MICs were variable, yet defined parameters to certain drugs-fluoroquinolones, pyrazinamide, clofazimine-were predictive and should be optimized to improve clinical outcome. CLINICAL TRIALS REGISTRATION: NCT03559582.","journal":"Clinical Infectious Diseases","year":2022,"id":261040,"datarank":0.6518984474376464,"base_score":2.772588722239781,"endowment":2.772588722239781,"self_citation_contribution":0.41588830833596724,"citation_network_contribution":0.23601013910167906,"self_endowment_contribution":0.41588830833596724,"citer_contribution":0.23601013910167906,"corpus_percentile":null,"corpus_rank":null,"citation_count":15,"citer_count":10,"citers_with_citation_signal":6,"citers_with_endowment":6,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9387,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT03559582"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":365122,"name":"Stellah Mpagama","orcid":"0000-0002-0660-6930","position":1,"is_corresponding":false},{"id":422666,"name":"О. Б. Огарков","orcid":"0000-0002-3168-1983","position":2,"is_corresponding":false},{"id":299095,"name":"Mark R. Conaway","orcid":"0000-0002-0459-2336","position":3,"is_corresponding":false},{"id":516292,"name":"Shahriar Ahmed","orcid":"0000-0002-8833-4130","position":4,"is_corresponding":false},{"id":915230,"name":"С. Н. Жданова","orcid":"0000-0001-7160-9700","position":5,"is_corresponding":false},{"id":494894,"name":"Suporn Pholwat","orcid":null,"position":6,"is_corresponding":false},{"id":336075,"name":"Mohammad H. Al‐Shaer","orcid":"0000-0003-1432-5175","position":7,"is_corresponding":false},{"id":915231,"name":"Anna M. Chongolo","orcid":"0000-0002-4151-9226","position":8,"is_corresponding":false},{"id":915850,"name":"Buliga Mujaga","orcid":null,"position":9,"is_corresponding":false},{"id":699409,"name":"Margaretha Sariko","orcid":"0000-0001-6264-773X","position":10,"is_corresponding":false},{"id":915232,"name":"Sabrina Saba","orcid":"0000-0002-3147-6998","position":11,"is_corresponding":false},{"id":915233,"name":"S. M. Mazidur Rahman","orcid":"0000-0003-2887-6250","position":12,"is_corresponding":false},{"id":915851,"name":"Mohammad Khaja Mafij Uddin","orcid":null,"position":13,"is_corresponding":false},{"id":915852,"name":"A. E. Suzdalnitsky","orcid":null,"position":14,"is_corresponding":false},{"id":915853,"name":"Elena Moiseeva","orcid":null,"position":15,"is_corresponding":false},{"id":422665,"name":"Elena Zorkaltseva","orcid":"0000-0002-9449-7577","position":16,"is_corresponding":false},{"id":915854,"name":"Mikhail Koshcheyev","orcid":null,"position":17,"is_corresponding":false},{"id":423419,"name":"Serhiy Vitko","orcid":null,"position":18,"is_corresponding":false},{"id":341832,"name":"Blandina T. Mmbaga","orcid":"0000-0002-5550-1916","position":19,"is_corresponding":false},{"id":661909,"name":"Gibson Kibiki","orcid":"0000-0002-2826-8709","position":20,"is_corresponding":false},{"id":915234,"name":"Jotam G. Pasipanodya","orcid":"0000-0002-8984-8379","position":21,"is_corresponding":false},{"id":267037,"name":"Charles A. Peloquin","orcid":"0000-0001-9002-7052","position":22,"is_corresponding":false},{"id":516294,"name":"Sayera Banu","orcid":"0000-0002-5121-1962","position":23,"is_corresponding":false},{"id":289258,"name":"Eric R. Houpt","orcid":"0000-0003-1085-1354","position":24,"is_corresponding":false},{"id":365125,"name":"Scott K. Heysell","orcid":"0000-0002-2040-0293","position":0,"is_corresponding":true}],"reference_count":25,"raw_metadata":null,"created_at":"2026-07-19T00:26:12.158801Z","pmid":"35731948","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}